Physician profile
Harkanwal Kaur
NPI 1154940245
$1,487.76
in general payments reported to CMS, 2019-2025
24 companies · $1,395 in 2025
The $1,395 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $92.64 · 2025: $1,395.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,488.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,487.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $386.93 | 2024-2025 | Repatha, Otezla, Evenity |
| Pfizer INC. | $168.03 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $165.51 | 2025 | Breztri, Farxiga, Airsupra |
| Exact Sciences Corporation | $83.93 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Lilly USA, LLC | $75.18 | 2025 | Jardiance, Zepbound, Mounjaro |
| Alnylam Pharmaceuticals INC. | $54.82 | 2025 | Amvuttra |
| Merck Sharp & Dohme LLC | $50.39 | 2025 | Capvaxive, Gardasil 9 |
| Abbvie INC. | $47.02 | 2025 | |
| Astellas Pharma US INC | $44.72 | 2025 | Veozah |
| Biosense Webster, INC. | $44.45 | 2024 | Qdot Micro Catheter |
| Sanofi Pasteur INC. | $43.84 | 2025 | |
| Esperion Therapeutics, INC. | $38.61 | 2025 | Nexletol |
| Lundbeck LLC | $34.10 | 2025 | Rexulti |
| Neurocrine Biosciences, INC. | $31.95 | 2025 | |
| Radius Health, INC. | $27.15 | 2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, INC. | $25.82 | 2025 | Rexulti |
| Biogen, INC. | $25.30 | 2025 | Leqembi |
| Dynavax Technologies Corporation | $24.81 | 2025 | Heplisav-B |
| Hologic Sales and Service, LLC | $24.66 | 2025 | Thinprep 2000 Processor, Aptima |
| Otsuka America Pharmaceutical, INC. | $22.85 | 2025 | Rexulti |
| Eisai INC. | $19.53 | 2025 | |
| Seqirus USA INC | $17.41 | 2025 | Fluad, Flucelvax |
| Novo Nordisk INC | $15.65 | 2025 | Ozempic |
| Novartis Pharmaceuticals Corporation | $15.10 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harkanwal Kaur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.